Pazopanib for metastatic soft-tissue sarcoma: A multicenter retrospective study.

Sinan KocaMehmet BeşiroğluMelike ÖzçelikMustafa KaracaMehmet BiliciBekir HacıoğluGamze G DoğuNihal B KaplanZeynep OruçDinçer AydınFaysal Dane

Published in: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners (2020)

Pazopanib is an efficient and tolerable agent and is well tolerated in good performance status patients with relapsed, advanced non-adipocytic soft tissue sarcomas.

Keyphrases

soft tissue
metastatic renal cell carcinoma
acute lymphoblastic leukemia
acute myeloid leukemia
squamous cell carcinoma
small cell lung cancer
multiple myeloma
diffuse large b cell lymphoma
hodgkin lymphoma
high grade
cross sectional
double blind
clinical trial